We examined alterations in these genes in the different PARPi-resistant tumor groups with informed HR status, i.e., (1) RAD51-positive KB1P(M), (2) RAD51-negative KB1P(M), and (3) KB2P tumors. The gene discussed is RAD51; the disease is neoplasm.